Sage Therapeutics Inc (NASDAQ:SAGE) price on Tuesday, December 24, rose 0.74% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.48.
A look at the stock’s price movement, the close in the last trading session was $5.44, moving within a range at $5.09 and $5.505. The beta value (5-Year monthly) was 0.924. Turning to its 52-week performance, $28.26 and $4.62 were the 52-week high and 52-week low respectively. Overall, SAGE moved 6.00% over the past month.
Sage Therapeutics Inc’s market cap currently stands at around $337.69 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 13.97M for the company’s revenue for the quarter, with a low and high estimate of 10.35M and 16.3M respectively. The average forecast suggests down to a -82.08% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 42.1M, representing a -51.31% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SAGE is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 3 recommend SAGE as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SAGE’s current price about -0.58% and -9.32% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 47.94, while 7-day volatility ratio is 8.42% and 7.00% in the 30-day chart. Further, Sage Therapeutics Inc (SAGE) has a beta value of 0.92, and an average true range (ATR) of 0.40. Analysts have given the company’s stock an average 52-week price target of $13, forecast between a low of $4 and high of $26. Looking at the price targets, the low is 27.01% off current price level while to achieve the yearly target high, price needs to move -374.45%. Nonetheless, investors will most likely welcome a -137.23% jump to $13 which is the analysts’ median price.
If we refocus on Sage Therapeutics Inc (NASDAQ:SAGE), historical trading data shows that trading volumes averaged 1.91 over the past 10 days and 922.87K over the past 3 months. The company’s latest data on shares outstanding shows there are 61.17 million shares.
The 11.92% of Sage Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 85.29% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.53 million on 2024-11-29, giving us a short ratio of 7.21. The data shows that as of 2024-11-29 short interest in Sage Therapeutics Inc (SAGE) stood at 1209.00005 of shares outstanding, with shares short rising to 6.0 million registered in 2024-10-31. Current price change has pushed the stock -74.71% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SAGE stock continues to rise going into the next quarter.
